Telbivudine　(beta-L-2＇-deoxythymidine)　is　an　orally　administered　nucleoside　analog　drug　approved　for　the　treatment　of　patients　with　chronic　hepatitis　B　since　2006.　Initially,　it　was　regarded　as　being　generally　well　tolerated,　with　low　adverse　reaction　profiles　and　no　dose-limiting　toxicity.　Recently,　with　the　result　of　the　telbivudine　worldwide　phase　III　GLOBE　trial　and　other　clinical　experiments,　cases　of　myopathy　and　neuropathy　have　been　reported　undergoing　long-term　telbivudine　treatments.　Telbivudine-induced　myopathy　has　been　characterized　by　muscle　pain,　weakness　and　moderately　elevated　creatine　kinase　levels　during　treatments,　although　no　severe　adverse　events　have　been　observed.　Rhabdomyolysis　has　not　reported　in　any　patient.